Axogen reports preliminary Q4 revenue $42.7M (+18% YoY); CEO Karen Zaderej to retire by Jan 2025

Axogen, Inc.

Q4 revenue $42.7M (+18% YoY); FY2023 revenue $158.8M (+15% YoY) at high end of $154-159M guidance.
Gross margin for FY2023 expected ~80%; 375 Core Accounts (+13% YoY); 116 direct sales reps.
CEO Karen Zaderej to retire by Jan 2025; Board will search for successor; she will consult for 9 months after transition.
BLA submission for Avance Nerve Graft on track for H1 2024; Axoguard HA+ and Avive+ product rollouts planned.
Avance Nerve Graft surpassed 100,000 implants since launch; strong commercial execution cited.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Karen Zaderej

Chief Executive Officer and President

AXGN · Axogen, Inc.

Filed: January 4, 2024, 6:59 PM ET

Retirement of Karen Zaderej Karen Zaderej, the Chief Executive Officer (the “CEO”) and President of the Company informed the Company of her intention to retire in January 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Axogen, Inc. reported full year 2023 results: revenue $158.8 million. Guidance reaffirmed.

Period: full year 2023
Revenue: $158.8 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Full-year 2023 revenue is expected to be approximately $158.8 million, which represents a 15% increase over the full-year of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Axogen, Inc. reported fourth quarter 2023 results: revenue $42.7 million.

Period: fourth quarter 2023
Revenue: $42.7 million
Result: preliminary results

Exact text from the filing

Fourth quarter revenue is expected to be approximately $42.7 million, which represents an 18% increase over the fourth-quarter of 2022 driven by solid performance across the product portfolio.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Karen Zaderej departed as Chief Executive Officer and President at Axogen, Inc..

Action: retire
Role: Chief Executive Officer and President

Exact text from the filing

Retirement of Karen Zaderej Karen Zaderej, the Chief Executive Officer (the “CEO”) and President of the Company informed the Company of her intention to retire in January 2025.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0000805928-24-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.